Angelini Pharma has hired Thomas Michael Thestrup, formerly of UCB and Lundbeck, to work on its innovation team.
Thomas Michael Thestrup, formerly director for corporate business development and strategy for Denmark-listed pharmaceutical group Lundbeck, has joined Italy-based peer Angelini Pharma’s corporate venturing department as investment director.
Thestrup said: I will be working with Angelini’s R&D [research and development] external innovation team, Lumira Ventures and our joint Angelini Lumira Biosciences Fund and ArgoBio Studio.
“Looking forward to an exciting adventure investing in innovative and novel sciences and building companies that can help people with [central nervous system] and rare diseases.”
Prior to joining Lundbeck…